BioSpace News Archive

According to a recent report published by Forbes, Brightfield Group indicated that the global cannabis market value had crossed the USD 7.5 Billion mark at the end of 2017 and is projected to breach USD 30 Billion by 2021.

Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of HulioTM (Product Code: FKB327), the companies’ biosimilar to Humira® (adalimumab), for all indications.

Zynex announced today that it will host the Company’s 2018 second quarter investor webcast on Thursday, August 2, 2018 at 11:00 a.m. Mountain Time (1:00 p.m. Eastern Time.)

Healthcare market researcher Kalorama Information believes this week’s vote to repeal the medical device tax in the House could have real effects on a relatively slow-growing U.S. device market, though those effects might be long-term.

Physio-Control, now part of Stryker, today announced it has received premarket approval by the U.S. Food and Drug Administration (FDA) to continue to market and distribute its full line of LIFEPAK professional defibrillators in the U.S.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the closing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $15.00 per share.

Legal actions filed by two patients with HIV from Louisiana targets Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).

PERSERIS is the first once-monthly subcutaneous risperidone-containing long-acting injectable

Hologic, Inc. (Nasdaq: HOLX) announced today that a jury in the U.S. District Court for the District of Delaware awarded Hologic $4.8 million in damages for Minerva Surgical’s infringement of two Hologic patents related to endometrial ablation technology.

Beacon Point brings quality-care to the heart of the epidemic in Philadelphia